ABCL

AbCellera Biologics Inc

11.80

Nov 13 • 5:10 AM ET +0.18 (1.55%)

Healthcare Biotechnology Canada Mid NASD

Peers: ABSI OABI RXRX XNCR ZYME TWST LGND SDGR DNA ADAG

| Held by: IBB IDNA SPDW FDT ONEQ AVUS BBC AVSC PDN IBBQ

Scroll to Statements

Index	-
Market Cap	3.85B
Enterprise Value	3.20B
Income	-148.30M
Sales	67.86M
Book/sh	3.26
Cash/sh	2.42
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	562
IPO	Dec 11, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	56.79
P/B	3.62
P/C	4.88
P/FCF	-
EV/EBITDA	-
EV/Sales	47.13
Quick Ratio	12.33
Current Ratio	12.43
Debt/Eq	0.13
LT Debt/Eq	0.12
Option/Short	Yes / Yes

EPS (ttm)	-0.48
EPS next Y	-0.65
EPS next Q	-0.16
EPS this Y	-24.58%
EPS next Y	-5.97%
EPS next 5Y	-13.11%
EPS past 3/5Y	- -
Sales past 3/5Y	-46.31% -20.27%
EPS Y/Y TTM	16.43%
Sales Y/Y TTM	92.10%
EPS Q/Q	32.97%
Sales Q/Q	18.81%
Earnings	Nov 09 AMC
EPS/Sales Surpr.	23.80% 26.41%

Insider Own	21.74%
Insider Trans	0.09%
Inst Own	35.28%
Inst Trans	-3.90%
ROA	-10.39%
ROE	-14.64%
ROIC	-12.46%
Gross Margin	49.93%
Oper. Margin	-297.97%
Profit Margin	-218.54%
SMA20	-2.43%
SMA50	-4.40%
SMA200	63.01%
Trades

Shs Outstand	326.33M
Shs Float	255.61M
Short Float	11.35%
Short Ratio	5.70
Short Interest	29.02M
52W High	15.02 -21.41%
52W Low	2.74 329.87%
Volatility	8.04% 8.05%
ATR (14)	0.91
RSI (14)	47.42
Beta	1.59
Rel Volume	0.04
Avg Volume	5.09M
Volume	9,707

Perf Week	-0.67%
Perf Month	-6.94%
Perf Quarter	5.36%
Perf Half Y	188.51%
Perf YTD	245.03%
Perf Year	225.97%
Perf 3Y	196.48%
Perf 5Y	-21.44%
Perf 10Y	-
Recom	1.14
Target Price	18.00
Prev Close	11.62
Price	11.80
Change %	1.55%

Consensus

Strong Buy

Avg. Price Target

$18.00

Implied Upside

+52.5%

Analysts13incl. previous ratings

Rating Distribution11 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 12, 2026	Initiated	UUBS	Buy	$18	+52.5%
Sep 29, 2026	Initiated	JJP Morgan	Overweight	$17	+44.1%
Sep 24, 2026	Initiated	GGoldman	Neutral	$13	+10.2%
Jul 07, 2026	Upgrade	TThe Benchmark Company	Hold → Buy	$11	-6.8%
May 05, 2026	Initiated	CCantor Fitzgerald	Overweight	$7	-40.7%
Nov 07, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform	$4	-66.1%
Jul 07, 2025	Resumed	LLeerink Partners	Outperform	$5	-57.6%
Aug 20, 2024	Downgrade	TThe Benchmark Company	Buy → Hold
Feb 22, 2024	Upgrade	TThe Benchmark Company	Hold → Buy	$9	-23.7%
Dec 05, 2023	Initiated	KKeyBanc Capital Markets	Overweight	$6	-49.2%
Nov 06, 2023	Downgrade	TThe Benchmark Company	Buy → Hold
Oct 13, 2023	Resumed	PPiper Sandler	Overweight	$20	+69.5%
Feb 28, 2023	Initiated	CCowen	Outperform
Dec 15, 2022	Initiated	GGoldman	Buy	$30	+154.2%
Nov 16, 2022	Initiated	TTruist	Buy	$29	+145.8%
Dec 21, 2021	Initiated	TThe Benchmark Company	Buy	$27	+128.8%
Nov 19, 2021	Initiated	PPiper Sandler	Overweight	$33	+179.7%
Jan 05, 2021	Initiated	SSVB Leerink	Outperform	$45	+281.4%
Jan 05, 2021	Initiated	SStifel	Buy	$59	+400.0%
Jan 05, 2021	Initiated	CCredit Suisse	Outperform	$52	+340.7%

Nov-09-26 08:48PM	AbCellera Tops Estimates, But ABCL635's Breakout Phase 2 Data And A $900 Million War Chest Are The Real Story (Earnings Whispers) +5.22%
03:05PM	AbCellera Reports Q3 2026 Business Results (Business Wire)
Nov-02-26 04:25PM	AbCellera Heads Into Results With Stock Doubled And ABCL635 Phase 2 Data Taking Center Stage (Earnings Whispers) -9.37% +9.53%
Oct-08-26 07:58PM	What Could Go Wrong With Recursion Pharmaceuticals Stock? (Trefis) -6.31%
04:05PM	AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting (Business Wire)
04:05PM	Loading…
Oct-01-26 04:05PM	AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 (Business Wire)
12:11PM	AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment (PR Newswire)
Sep-29-26 10:57PM	Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today? (Stocktwits) +6.47%
Sep-16-26 04:05PM	AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 (Business Wire) +9.08%
Sep-02-26 04:05PM	AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 (Business Wire)
Aug-13-26 12:05AM	AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants (Business Wire) +5.94%
Aug-11-26 04:01PM	AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) +6.10%
Aug-10-26 10:31PM	Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? (Stocktwits) +34.78%
12:15PM	Hot-Flash Drug Trial Result Sends AbCellera Up as Much as 41% (Bloomberg)
12:05PM	AbCellera Stock Jumps 33% on a Positive Menopause Trial (GuruFocus.com)
08:45AM	Loading…
08:45AM	AbCellera shares surge 22% after ABCL635 delivers positive Phase 2 results (InvestorsHub)
07:23AM	This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News. (Barrons.com)
07:00AM	AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile (Business Wire)
06:52AM	ABCL Stock On Track For Best Day In Nearly 4.5 Years After Positive Phase 2 Menopause Drug Data (Stocktwits)
06:52AM	ABCL Stock Has Rallied 100% This Year Now All Eyes Are On AbCelleras Menopause Drug Data (Stocktwits)
Aug-07-26 04:30PM	AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 (Business Wire) +6.13%
Aug-06-26 01:01AM	AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ... (GuruFocus.com) +10.30%
Aug-05-26 04:05PM	AbCellera Reports Q2 2026 Business Results (Business Wire)
Jul-29-26 07:00AM	AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions (Business Wire)
Jul-23-26 09:05AM	An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers (PR Newswire)
Jul-15-26 08:45AM	As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22 (PR Newswire)
Jul-07-26 04:05PM	AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 (Business Wire) -7.67%
Jul-06-26 09:00AM	AbCellera Appoints Dr. Lynn Seely to its Board of Directors (Business Wire)
Jul-01-26 09:00AM	As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data (PR Newswire)
Jun-28-26 11:56PM	Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? (Stocktwits)
08:50AM	Loading…
Jun-17-26 08:50AM	Jazz Pharmaceuticals and AbCellera Partner on Antibody Programs for Solid Tumors (InvestorsHub) +6.88%
07:00AM	Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies (PR Newswire)
Jun-05-26 09:00AM	AbCellera Appoints Dr. Victor Sandor to its Board of Directors (Business Wire) -11.77%
May-12-26 03:07AM	AbCellera Biologics Inc (ABCL) Q1 2026 Earnings Call Highlights: Promising Advancements Amid ... (GuruFocus.com) -5.71%
May-11-26 04:05PM	AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 (Business Wire)
May-07-26 04:05PM	AbCellera to Present at Upcoming Investor Conferences in May and June 2026 (Business Wire) +8.71%
Apr-20-26 09:00AM	AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call (Business Wire)
Apr-01-26 04:05PM	AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 (Business Wire)
Mar-04-26 11:50AM	AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says (MarketBeat)
Feb-26-26 02:28PM	AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M (Insider Monkey) +12.54%
Feb-25-26 03:51AM	What Sparked AbCellera Biologics To Soar Over 9% After Hours (Benzinga)
12:00AM	AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
Feb-24-26 09:55PM	AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.27%
06:26PM	AbCellera Biologics Q4 Earnings Call Highlights (MarketBeat)
04:05PM	AbCellera Reports Full Year 2025 Business Results (Business Wire)
Feb-19-26 07:30AM	3 New Stocks SoftBank Is Betting Big on in 2026 (Barchart)
Feb-18-26 09:43AM	SoftBank Adds TwentyOne Capital, Exits Nvidia in Q4 Portfolio Shift (GuruFocus.com)
Feb-11-26 04:05PM	AbCellera to Present at Upcoming Investor Conferences in March and April 2026 (Business Wire) -6.07%
Feb-02-26 07:49PM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jan-29-26 01:49PM	What Does Wall Street Think About AbCellera Biologics Inc. (ABCL)? (Insider Monkey)
Jan-22-26 04:05PM	AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 (Business Wire) +8.41% -8.62%
Jan-14-26 08:07PM	AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 (MarketBeat)
Jan-12-26 09:00AM	AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause (Business Wire)
Dec-08-25 04:05PM	AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 (Business Wire)
Dec-04-25 10:09PM	AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results (Insider Monkey)
Nov-25-25 08:16AM	AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss (Insider Monkey)
Nov-18-25 06:17AM	Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? (Insider Monkey)
Nov-07-25 12:12AM	AbCellera Biologics Inc (ABCL) Q3 2025 Earnings Call Highlights: Transition to Clinical-Stage ... (GuruFocus.com) -13.69%
Nov-06-25 05:45PM	AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q3 2025 Business Results (Business Wire)
Oct-21-25 10:47PM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Oct-07-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 (Business Wire) +6.93%
Sep-30-25 09:40AM	Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-29-25 04:05PM	AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
12:00PM	AbCellera Biologics Inc. (ABCL) is a Great Momentum Stock: Should You Buy? (Zacks)
Sep-21-25 09:26AM	New CMO Appointment Strengthens AbCellera Biologics Inc. (ABCL)'s Push Into Immunology and Beyond (Insider Monkey)
Sep-20-25 02:43AM	AbCellera Biologics Inc. (ABCL) Appoints Chief Medical Officer (Insider Monkey)
Sep-15-25 08:17AM	TD Cowen Reiterates Buy Rating on ABCL After AbCellera Biologics Dosed First Participants of ABCL575 (Insider Monkey)
Sep-10-25 09:07AM	AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer (Business Wire)
Aug-28-25 05:04AM	AbCellera Biologics Inc. (ABCL) Launches First Human Trial for Menopause Therapy (Insider Monkey)
Aug-27-25 09:00AM	AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 (Business Wire)
Aug-25-25 11:56PM	Truist Financial Reiterates a Buy Rating on AbCellera Biologics (ABCL), Sets a $10 PT (Insider Monkey)
Aug-17-25 06:10PM	AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial Results (Insider Monkey)
Aug-12-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in September (Business Wire) -5.11% +7.26%
Aug-08-25 03:42AM	AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... (GuruFocus.com)
Aug-07-25 06:20PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms (Business Wire)
Aug-05-25 05:55PM	Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates (Zacks) -5.50%
Jul-31-25 10:00AM	AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-25 10:06AM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jul-22-25 11:03AM	Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot (Insider Monkey)
09:39AM	Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Jul-07-25 04:05PM	AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire) +6.05%
09:11AM	Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating (Insider Monkey)
Jun-25-25 04:09AM	AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology (Insider Monkey)
Jun-09-25 09:13AM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jun-03-25 12:00PM	ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why (Zacks) +7.94%
Jun-02-25 06:45PM	Why AbCellera Biologics Stock Raced Nearly 6% Higher Today (Motley Fool) +5.94%
May-30-25 01:00PM	AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 (Business Wire)
May-21-25 11:21AM	AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential (Insider Monkey)
May-14-25 05:00PM	AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause (Business Wire)
May-12-25 03:30PM	AbCelleras Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit (Business Wire)
May-09-25 07:30PM	AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting (Business Wire)
11:22AM	Q1 2025 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
03:50AM	AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-08-25 06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q1 2025 Business Results (Business Wire)
May-07-25 12:39PM	AbCellera Biologics Q1 2025 Earnings Preview (Seeking Alpha)
10:45AM	AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-29-25 03:00PM	AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thermopylae Holdings Ltd.	10% Owner	Nov 12 '26	Buy	11.54	60,565	698,920	56,194,662	Nov 12 01:15 PM

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Veronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

CEODr. Carl L.G. Hansen Ph.D.

Chief Financial OfficerMr. Andrew Booth M.B.A.

CTO & DirectorDr. Veronique Lecault Ph.D.

J.D.Mr. Tryn T. Stimart Esq.

Vice President of OperationsMr. Andrew Knowles M.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

ABCL

AbCellera Biologics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.